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Variability in the performance of nucleic acid ampliﬁcation technology (NAT)-based assays presents a
signiﬁcant problem in the diagnosis andmanagement of human cytomegalovirus (HCMV) infections. Here
we describe a collaborative study to evaluate the suitability of candidate referencematerials to harmonize
HCMV viral load measurements in a wide range of NAT assays. Candidate materials comprised lyophilized
Merlin virus, liquidMerlin virus, liquid AD169 virus, and puriﬁed HCMVMerlin DNA cloned into a bacterial
artiﬁcial chromosome. Variability in the laboratory mean HCMV concentrations determined for virus
samples across the different assays was 2 log10. Variability for the puriﬁed DNA sample was higher (>3
log10). The agreement between laboratorieswasmarkedly improvedwhen the potencies of the liquid virus
samples were expressed relative to the lyophilized virus candidate. In contrast, the agreement between
laboratories for the puriﬁed DNA sample was not improved. Results indicated the suitability of the
lyophilized Merlin virus preparation as the 1st WHO International Standard for HCMV for NAT. It was
established in October 2010, with an assigned potency of 5  106 International Units (IU) (NIBSC code 09/
162). It is intended to be used to calibrate secondary references, used in HCMV NAT assays, in IU.
© 2016 The Authors. Published by Elsevier Ltd on behalf of International Alliance for Biological
Standardization. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Human cytomegalovirus (HCMV) is a ubiquitous herpesvirus
which causes disease in the immunologically-naïve, such as new-
borns and infants, and in immunosuppressed individuals, particu-
larly transplant recipients and AIDS patients. Severe and life-
threatening HCMV infections in immunocompromised individuals
are managed with antiviral drugs, however, toxicity is associated
with their prolonged use. The clinical utility of HCMV viral load
measurements using nucleic acid ampliﬁcation technology (NAT),
for the diagnosis, prevention and treatment of disease in transplant
recipients has been described [1]. Guidelines recommend using
NAT to monitor HCMV load during pre-emptive antiviral therapy in
order to guide the initiation of and determine the duration of
treatment [2e4]. Antiviral drugs are deployed when pre-
determined levels predictive of disease are reached. Although
there is no consensus on the optimal sample type or frequency ofer).
the Acknowledgements.
Ltd on behalf of International Allian
c-nd/4.0/).testing, both plasma and whole blood provide pertinent informa-
tion relevant to the diagnosis and prognosis of HCMV disease.
A wide variety of different NAT assays are used to determine
HCMV viral load measurements. Many sites use laboratory-
developed tests (LDTs) based on real-time PCR. A number of com-
mercial assays are also available, comprising either analyte-speciﬁc
reagents (ASR) or assay kits speciﬁc for different ampliﬁcation
platforms. Assays differ in the specimen tested (whole blood,
plasma, serum, urine, CSF, etc), nucleic acid extraction protocol, PCR
reagents (including primers and probes) and instrumentation used.
Quantitative assays require control materials to determine the
concentration of viral DNA present. These may comprise either a
plasmid clone of the PCR target, or quantiﬁed viral DNA or virus
particles, and depending upon the assay design, these may be
excluded from the extraction step.
Given the heterogeneity of these NAT-based assay systems, and
the lack of traceability to a standardized reference system, it is
difﬁcult to compare viral load measurements between different
laboratories and to establish internationally applicable quantitative
cut-off values for the diagnosis and treatment of CMV disease.
Indeed, variability in the performance of different assays for HCMVce for Biological Standardization. This is an open access article under the CC BY-NC-
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need for an internationally-accepted reference standard for HCMV.
In 2004, the International Herpes Management Forum called for;
‘an international quantiﬁcation standard… to compare studies us-
ing different PCR-based systems and to facilitate patient manage-
ment at multiple care centres’ [2]. In the absence of such a standard,
pre-existing clinical guidelines recommended that individual lab-
oratories establish their own viral load cut-off values for HCMV
management, which are speciﬁc to their laboratory assay [7].
The World Health Organization's (WHO) Expert Committee on
Biological Standardization (ECBS) establishes reference standards
for biological substances used in the prevention, treatment or
diagnosis of human disease. WHO International Standards are
recognized as the highest order of reference for biological sub-
stances, and are arbitrarily assigned a potency in International
Units (IU). Their primary purpose is to calibrate secondary refer-
ences used in routine laboratory assays, in terms of the IU, thereby
providing a uniform result reporting system, and traceability of
measurements, independent of the method used [8]. WHO Inter-
national Standards for NAT for the blood-borne viruses have been
shown to greatly improve the comparability of NAT assays used in
blood safety and clinical ﬁelds [9].
Proposals for the development of the 1st WHO International
Standard for HCMV were presented at the ﬁrst SoGAT Clinical Di-
agnostics meeting held at NIBSC in June 2008 [10], and options for
source materials and formulation of the candidate standards were
discussed (http://www.nibsc.org/PDF/SoGAT%20Clinical%
20Diagnostics%20I%202008%20Report.pdf). These proposals have
now been realized through the development of candidate reference
materials, evaluation of these in an international collaborative
study, and establishment of the optimal candidate as the 1st WHO
International Standard for HCMV for NAT.
2. Materials and methods
2.1. Preparation of candidate stock materials
Candidate materials comprised whole virus preparations of
Merlin [11] and AD169 [12], a lyophilized whole virus Merlin
preparation, and full-length Merlin DNA cloned into a bacterial
artiﬁcial chromosome (BAC) [13]. Merlin and AD169 strains (kindly
provided by Professor Wilkinson, Cardiff University, Cardiff, UK)
were propagated in MRC-5 cells (NIBSC, Potters Bar, UK), in roller
bottles. Tissue culture ﬂuid was harvested once a cytopathic effect
(CPE) was observed, and repeated until all the cells showed CPE.
The culture supernatant was clariﬁed by low speed centrifugation
(3900 g) and the virus was pelleted by ultracentrifugation
(48,000 g). Virus stocks were prepared by reconstituting virus
pellets and pooling in a total volume of 200 mL of 10 mM TriseHCl
buffer (pH 7.4), containing 0.5% human serum albumin (HSA)
(TriseHSA buffer). The HSA used in the preparation of these
candidate materials was derived from licensed products, and was
screened and tested negative for anti-HIV-1, HBsAg, and HCV RNA.
Virus stocks were stored at 70 C until use. The Merlin BAC
(pAL1128) (kindly provided by Professor Wilkinson, Cardiff Uni-
versity) had been prepared from the complete HCMV Merlin
genome [13] (HCMV component sequenced, GenBank Accession
number GU179001). BAC DNA was puriﬁed using a Nucleobond
BAC100 kit (Machery-Nagel GmbH, Düren, Germany) according to
manufacturer's instructions.
2.2. HCMV DNA quantiﬁcation
The HCMV concentration of the Merlin and AD169 virus stocks
was determined using a quantitative real-time PCR LDT (modiﬁedfrom Ref. [14]). Brieﬂy, 400 mL of sample was extracted using the
QIAamp® MinElute® Virus Spin Kit on the QIAcube® instrument
(both QIAGEN, Hilden, Germany), and eluted into a ﬁnal volume of
50 mL. Fivemicrolitres of puriﬁed nucleic acidwas then ampliﬁed by
real-time PCR, using the LightCycler® 480 Instrument (Roche
Applied Science, Mannheim, Germany). The target was quantiﬁed
against serial dilutions of a plasmid clone of the PCR target. All
samples were ampliﬁed in triplicate. The HCMV DNA concentration
of the virus stocks was also determined using the LightCycler® CMV
Quant Kit (Roche Diagnostics GmbH, Mannheim, Germany) and the
Q-CMV Real Time Complete Kit (Nanogen Advanced Diagnostics
S.r.L., Buttigliera Alta, Italy), and in ﬁve clinical laboratories in the
UK using a range of LDT and commercial assays. The geometric
mean virus concentration from all assays, in ‘copies/mL’, was used
to determine a consensus HCMV concentration for each stock. The
concentration of puriﬁed BAC DNA was determined by absorbance
at 260 nm using a NanoDrop ND-1000 spectrophotometer (Nano-
Drop Technologies Inc., Wilmington, DE).2.3. Preparation of the candidate bulks
Merlin and AD169 whole virus candidate bulk materials were
prepared by dilution of virus stocks in Tris-HSA buffer to a ﬁnal
concentration of 1  107 HCMV ‘copies/mL’. Samples were
dispensed in 1mL aliquots and stored at70 C until shipment. The
Merlin BAC bulk was prepared by dilution of the DNA stock in
nuclease-free water to a ﬁnal concentration of 1  105 HCMV
‘copies/mL’. The rationale for preparing the Merlin BAC bulk at this
concentration was to achieve broadly equivalent viral load de-
terminations to the whole virus samples which were to be pro-
cessed differently in the collaborative study evaluation (see Section
on 2.7). The Merlin BAC bulk was aliquotted in 50 mL volumes and
stored at 70 C until shipment. The HCMV DNA concentration in
each of these ﬁnal study samples was determined using the real-
time PCR LDT described above. The bulk for the lyophilized
Merlin preparation, was formulated to contain approximately
1  107 HCMV ‘copies/mL’ in a ﬁnal volume of 6.4 L Tris-HSA buffer.
The bulk was mixed for a total of 30 min using a magnetic stirrer
prior to ﬁlling.2.4. Filling and lyophilization of the Merlin candidate
The ﬁlling of the lyophilized Merlin candidate was performed in
a negative pressure isolator (Metall and Plastic GmbH, Radolfzell,
Germany), containing the entire ﬁlling line, which is interfaced
with a CS150 freeze dryer (Serail, Arguenteil, France). The bulk
material was kept at 4 C throughout the ﬁlling process and stirred
constantly using a magnetic stirrer. The bulk was dispensed into
5 mL screw cap glass vials in 1 mL volumes, using a FVF5060 ﬁlling
machine (Bausch & Strobel, Ilfshofen, Germany). The homogeneity
of the ﬁll was maintained by on-line check-weighing of the wet
weight (target weight of 1.000 g), and vials outside the deﬁned
speciﬁcation (0.993e1.008 g) were discarded.
Filled vials were partially stoppered with 14 mm diameter hal-
obutyl cruciform closures and lyophilized in the CS150 freeze dryer.
Vials were loaded onto the shelves at 50 C and held at this
temperature for 4 h. A vacuum was applied to 270 mb over 1 h
followed by ramping to 30 mb over 1 h. The temperature was then
raised to 40 C and the vacuum maintained at this temperature
for 42.5 h. The shelves were ramped to 25 C over 15 h before
releasing the vacuum and back-ﬁlling the vials with nitrogen. The
vials were then stoppered in the dryer, removed and capped in the
isolator, and the isolator decontaminated by fumigation with
formaldehyde vapour before removal of the product. The sealed
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monitoring for the lifetime of the product.
Assessments of residual moisture and oxygen content, as an
indicator of vial integrity after sealing, were determined for twelve
vials of freeze-dried product. Residual moisture was determined
using a non-invasive MCT 600P Near Infrared (NIR) Transmitter
(Process Sensors, Corby, UK). NIR results were then correlated to
Karl Fischer (using calibration samples of the same excipient,
measured using both NIR and Karl Fischer methods), to give % w/w
moisture readings. Oxygen content was measured using a FMS-750
Oxygen Headspace Analyzer (Lighthouse Instruments, Charlottes-
ville, VA).
2.5. Stability assessment of the lyophilized Merlin preparation
The stability of the lyophilized Merlin preparation is being
assessed in an on-going accelerated thermal degradation study in
order to predict the stability of the product when stored at the
recommended temperature of 20 C. Vials of the lyophilized
product are being held at70 C,20 C, 4 C, 20 C, 37 C, 45 C. At
speciﬁed time points during the life of the product three vials are
removed from storage at each temperature and HCMV DNA quan-
tiﬁed using the real-time PCR LDT described in Section 2.2.
2.6. Study participants
Thirty-two laboratories from 14 countries participated in the
collaborative study, and are listed in the Acknowledgements. Par-
ticipants were selected for their experience in HCMV NAT and
geographic distribution. They represented mainly clinical labora-
tories, but also included a range of manufacturers of in vitro diag-
nostic devices (IVDs), as well as reference, research and quality
assurance laboratories. All participating laboratories are referred to
by a code number, allocated at random, and not representing the
order of listing in the Acknowledgements. Where a laboratory
returned data using different assay methods, the results were
analyzed separately, as if from different laboratories, and are
referred to as, for example, laboratory 1A, 1B etc.
2.7. Study design
Study samples were coded as samples 1e4 and were as follows;
Sample 1, lyophilized Merlin virus; sample 2, liquid Merlin virus;
sample 3, liquid AD169 virus; and sample 4, liquid preparation of
puriﬁed BAC-cloned Merlin DNA. Four vials each of study samples
1e4 were delivered to participating laboratories by courier on dry
ice with speciﬁc instructions for storage and reconstitution. Par-
ticipants were requested to test dilutions of each sample using their
routine HCMV NAT assay, on four separate occasions, using a fresh
vial of each sample in each independent assay. The lyophilized
sample 1 was to be reconstituted with 1 mL of deionized nuclease-
free molecular-grade water and left for a minimum of 20 min with
occasional agitation before use. Meanwhile, study samples 2e4
were to be thawed and vortexed brieﬂy before use. For quantitative
assays, participants were requested to test a minimum of two serial
ten-fold dilutions within the linear range of the assay. For quali-
tative assays, participants were requested to test ten-fold serial
dilutions of each sample in the ﬁrst assay in order to determine the
assay end-point. Then to ﬁne tune the end-point by testing a
minimum of two half-log10 serial dilutions either side of the pre-
determined end-point for subsequent assays. Participants were
requested to dilute samples 1e3 using the sample matrix speciﬁc to
their individual assay and to extract each dilution prior to ampli-
ﬁcation. Meanwhile, participants were requested to dilute sample 4
in nuclease-free water and add an aliquot of each dilution directlyto the ampliﬁcation reaction. Participants were requested to report
the viral load in ‘copies/mL’ (positive/negative for qualitative as-
says) for each dilution of each sample, and to return results,
including details of the methodology used, to NIBSC for analysis.
2.8. Statistical methods
Qualitative and quantitative assay results were evaluated
separately. In the case of qualitative assays, for each laboratory and
assay method, data from all assays were pooled to give a number
positive out of a total number tested at each dilution step. A single
‘end-point’ for each dilution series was calculated, to give an esti-
mate of ‘NAT detectable units/mL’, as described previously [15]. In
the case of quantitative assays, analysis was based on the results
reported by the participants in copies/mL. For each assay run, a
single estimate of log10 ‘copies/mL’ was obtained for each sample,
by taking the mean of the log10 estimates of ‘copies/mL’ across
replicates, after correcting for any dilution factor. A single estimate
for the laboratory and assay method was then calculated as the
mean of the log10 estimates of ‘copies/mL’ across assay runs. Overall
analysis was based on the log10 estimates of ‘copies/mL’ or ‘NAT
detectable units/mL’. Overall mean estimates were calculated as the
means of all individual laboratories. Variation between laboratories
(inter-laboratory) was expressed as the SD of the log10 estimates
and percentage geometric coefﬁcient of variation (%GCV) [16] of the
actual estimates.
The ability of a candidate standard to reduce the inter-
laboratory variability in HCMV viral load measurements was
assessed by calculating the potency of one candidate relative to the
other study samples. The relative potency of, for example, sample 3
relative to sample 1 was calculated for each individual assay as the
difference in estimated log10 ‘units per mL’ (test sample e candi-
date standard) plus a candidate assigned value in IU/mL for the
candidate standard.
Variation within laboratories and between assays (intra-labo-
ratory), was expressed as the SDs of the log10 estimates and %GCVs
of the individual assay mean estimates. These estimates were
pooled across samples 1 to 3, but were calculated separately for
sample 4. The signiﬁcance of the inter-laboratory variation relative
to the intra-laboratory variation was assessed by an analysis of
variance.
3. Results
3.1. Validation of study samples and stability of the lyophilized
candidate
Evaluation of multiple aliquots (n ¼ 18) of each study sample
prior to dispatch indicated that the homogeneity of HCMV content
was similar for all study samples (2SD less than 0.3 log10 ‘copies/
mL’ for each sample). The mean and CV of the ﬁll weight for the
lyophilized Merlin candidate, were determined from measure-
ments from every 50th vial (n ¼ 126), and were 1 g and 0.23%,
respectively. The mean residual moisture, as determined by Karl
Fischer and NIR, was 0.6% and 0.41%, respectively (CV¼ 7.2%), based
on measurements from 12 vials. The mean residual oxygen content
was 0.22% (CV ¼ 40.6%), based on measurements from 12 vials. The
CV of the ﬁll mass and mean residual moisture were within
acceptable limits for a WHO International Standard [8]. Residual
oxygen content was within the NIBSC working limit of 1.1%.
The stability of the lyophilized Merlin candidate is being
assessed in accelerated thermal degradation studies. Vials are
stored at elevated temperatures and are removed at speciﬁc time
points for testing using the HCMV real-time PCR LDT. The mean
estimated HCMV concentration (in log10 ‘copies/mL’) for three vials
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are shown in Table 1. The differences in HCMV concentration from
the 20 C baseline sample are also shown. A negative value in-
dicates a drop in potency relative to the 20 C baseline. The 95%
conﬁdence intervals for the differences are ±0.16 log10 based on a
pooled estimate of the SD between individual vial test results. The
majority of temperatures and time points do not show any drop in
potency compared with the 20 C baseline samples. There is no
observable change in potency across the course of the 5 years at any
temperature, within the limits of the assay variability. However,
there does appear to be a pattern of an apparent increase in potency
with increasing temperature for the early time points. The reason
for this is unclear.
3.2. Data received
Data were received from all 32 participating laboratories. Par-
ticipants performed a variety of different assay methods with some
laboratories performingmore than one assaymethod. The variables
in assay methodologies used are detailed in Table 2. In total, data-
sets were received from 53 quantitative assays and 5 qualitative
assays. The majority of participants prepared dilutions of study
samples 1e3 using either plasma (30 datasets) or whole blood (25
datasets), however, urine, PBS, and nuclease-free water were also
used. The extent of the dilutions performed varied slightly between
each laboratory. Extractions were predominantly automated. The
majority of datasets reported the use of real-time PCR technology.
Seventeen participants used commercial assays and reagents (37
datasets), while 13 participants used laboratory-developed assays
(17 datasets). Two participants used both commercial and
laboratory-developed assays (4 datasets). Given the range of assay
combinations and variables, and the fact that no two assays were
alike (apart from two laboratories using the Roche COBAS®
AMPLICOR CMVMONITOR Test), it was not possible to group assays
and perform the analysis according to the methodology used.
Laboratory 31 had anomalous results for sample 1 in assay 4
(negative at 104.5 to 106 but positive at 106.5 dilutions). The
results for this assay were excluded from the analysis. Laboratories
2B, 4, 19B, 19C and 25 did not return results for sample 4. This was
principally because, for these assays, it was not possible to deter-
mine viral load without extracting the sample. Laboratory 12A
reported problems with their second assay for most replicates of
samples 1, 2& 3. This assay runwas excluded from further analysis.
Laboratory 16 only provided data from two assay runs. The second
assay tested extracted material that had undergone one freeze/
thaw cycle and was therefore excluded from the analysis. Labo-
ratory 22B returned data from four assay runs. However, the last
two runs tested samples that had undergone one freeze/thaw cycle
and were therefore excluded from the analysis. For some labora-
tories and assays, the results from individual dilutions were
excluded when they were noted as being outside the linear range
of the assays. Apart from the cases noted above, there were no
exclusions of data.Table 1
Thermal stability of lyophilized HCMV (Merlin strain), 09/162, at different storage tempe
Temperature (C) Mean log10 ‘copies/mL’ (difference in log10 ‘copies/mL’ fro
4 months 8 months 12 mo
70 6.92 6.77 6.86
20 6.92 6.78 6.85
4 6.86 (0.06) 6.72 (0.06) 6.77 (
20 6.96 (0.04) 6.84 (0.06) 6.89 (
37 7.02 (0.10) 6.91 (0.13) 6.94 (
45 7.07 (0.15) 6.97 (0.19) 6.99 (3.3. Potency estimates and inter-laboratory variation
The laboratory mean estimates for each study sample for
quantitative assays (in log10 ‘copies/mL’) and qualitative assays (in
log10 ‘NAT detectable units/mL’) are shown in Supplementary
Tables 1 and 2, respectively. The individual laboratory mean esti-
mates for each assay and study sample are also shown in histogram
form in Fig. 1. Results for samples 1e3 show considerable variation
in the viral load reported between different assays, with estimates
differing by up to 2 log10 ‘copies/mL’ (100-fold) (Supplementary
Table 1). The estimates from qualitative assays were typically
lower than those for quantitative assays. Meanwhile, the variability
for sample 4 was greater than that for samples 1e3, although, this
was principally due to outlying results from ﬁve different assays
(Fig. 1). Evaluation of the spread of results based on the dilution
matrix used in each assay showed that there was no observed
relationship between this and the HCMV concentration for each
sample (data not shown).
Table 3 shows the overall mean estimates for each study sample,
for quantitative and qualitative assays, along with the SD (of log10
estimates) and the %GCV (of actual estimates). For samples 1e3, the
SD for quantitative assays is approximately 0.5 log, and the %GCV is
approximately 200%. These ﬁgures are consistent with the
observed 2 log10 ‘copies/mL’ range of estimates. The spread for the
qualitative assays is similar. The SD and %GCV for sample 4 are
higher than those for samples 1e3, again, most likely due to the
outlying results.
Comparison of overall mean estimates for the lyophilizedMerlin
candidate sample 1 and liquid Merlin candidate sample 2 indicates
that there was no signiﬁcant loss in potency upon freeze-drying
(Table 3). In addition, comparison of overall mean estimates for
Merlin (sample 2) and AD169 (sample 3) liquid candidates indicates
the suitability of all assays to quantify equally these two strains.
3.4. Relative potency determination
The expression of the potency of the study samples relative to
the candidate standard (as described in Section 2.8), allows an
assessment of the suitability of a candidate for the standardiza-
tion of HCMV viral load measurements by NAT. The relative po-
tencies of study samples 2e4 against candidate sample 1, for each
quantitative and qualitative assay, are shown in histogram form
in Fig. 2. Units are expressed as candidate log10 IU/mL. The overall
mean relative potency estimates (in ‘candidate log10 IU/mL’) for
samples 2e4, for quantitative and qualitative assays, along with
the SD (of log10 estimates) and the %GCV (of actual estimates), are
shown in Table 4. Fig. 2 and Table 4 show that when the mean
estimates of samples 2 and 3 are expressed relative to sample 1,
there is a marked improvement in agreement between labora-
tories, compared with Fig. 1 and Table 3. While the results from
the qualitative assays remain more variable, they are now centred
around the overall mean HCMV estimate. For the quantitative
assays, the SD has reduced from approximately 0.5 log10 to 0.12ratures.
m 20 C baseline sample)
nths 29 months 45 months 60 months
6.81 6.73 6.85
6.62 6.70 6.80
0.08) 6.76 (0.14) 6.70 (0.00) 6.96 (0.16)
0.04) 6.87 (0.25) 6.90 (0.20) 6.95 (0.15)
0.09) 6.91 (0.29) 6.88 (0.18) 6.88 (0.08)
0.14) 6.92 (0.30) 6.82 (0.12) 6.89 (0.09)
Table 2
Summary of assay methodologies.
Assay component Variable
Diluent Plasma, whole blood, urine, PBS, nuclease-free water.
Extraction (automated) Abbott m2000sp; QIAGEN QIAsymphony SP and RG Q, BioRobot, MDx, and EZ1; bioMerieux NucliSENS® easyMag®;
Roche MagNA Pure LC and COBAS® AmpliPrep; Siemens VERSANT® kPCR.
Extraction (manual) Roche High Pure Viral Nucleic Acid Kit; Nanogen EXTRAgen®; QIAGEN QIAamp (Blood DNA, DNA and Viral RNA) Mini
Kits, QIAGEN QIAamp DSP Virus Kit; Cepheid afﬁgene® DNA Extraction Kit; phenol-chloroform extraction.
Ampliﬁcation kit/ASR (commercial assays) Roche COBAS® AMPLICOR CMV MONITOR Test; Nanogen Q-CMV Real Time Complete Kit; Argene CMV R-gene™ and
CMV HHV6,7,8 R-gene™; QIAGEN artus CMV (LC and RG) PCR Kits; Roche COBAS® TaqMan® CMV Test; Cepheid
afﬁgene® CMV trender and SmartCMV™; Abbott RealTime CMV (in development in 2010); ‘ELITech/Epoch CMV 3.0’;
Quantiﬁcation of CMV PrimerDesign™ Ltd.
HCMV gene target UL122/UL123 (immediate-early proteins), UL54 (DNA polymerase), UL83 (tegument protein pp65), UL55 (envelope
glycoprotein B), US8 (membrane glycoprotein), UL34 (nuclear egress membrane protein) and UL80.5 (capsid assembly
protein precursor).
Ampliﬁcation platform Roche LightCycler® 1.5, 2.0 and 480 systems, COBAS® TaqMan® and COBAS® AMPLICOR Analyzer; Applied Biosystems™
7300, 7500, 7500 Fast, and 7900 HT Fast Real-Time PCR Systems; Agilent Mx3000P® qPCR System; QIAGEN Rotor-Gene
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4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0
Fig. 1. Individual laboratory mean estimates for study samples 1 (A), 2 (B), 3 (C), and 4 (D), obtained using qualitative or quantitative NAT assays. Each box represents the mean
estimate from each laboratory assay and is labelled with the laboratory code number. The results from the qualitative assays are shaded in grey.
J.F. Fryer et al. / Biologicals 44 (2016) 242e251246log10 and 0.19 log10 for samples 2 and 3 respectively. However,
when the mean estimates of sample 4 are expressed relative to
sample 1 (Fig. 2), there is no signiﬁcant improvement in agree-
ment between laboratories, compared with Fig. 1. There is no
reduction in the SD for quantitative assays. As sample 1 requiresextraction, and sample 4 does not, differences in extraction efﬁ-
ciency between laboratories and methods still contribute to the
observed variation between laboratories for sample 4. These re-
sults suggest that using sample 1 as an International Standard
would signiﬁcantly improve the agreement in HCMV estimates
Table 3
Overall mean estimates and inter-laboratory variation (log10 ‘copies/mL’ for quan-
titative or ‘NAT-detectable units/mL’ for qualitative assays).
Sample Assay No. of datasets Mean Range SD %GCV
1 qualitative 5 6.01 5.39e6.55 0.42 161
quantitative 53 6.71 5.65e7.46 0.46 188
2 qualitative 5 5.93 5.47e6.43 0.46 185
quantitative 53 6.71 5.58e7.53 0.49 207
3 qualitative 5 5.86 5.18e6.62 0.54 249
quantitative 52 6.72 5.73e7.39 0.46 190
4 qualitative 5 6.82 6.51e7.16 0.25 77
quantitative 48 7.11 5.06e8.81 0.61 307
J.F. Fryer et al. / Biologicals 44 (2016) 242e251 247between assays testing virus-based samples similar to study
samples 2 and 3.
The estimated concentrations of samples 1e3 were also
expressed in ‘candidate IU’, relative to sample 4, using a hypo-
thetical unitage of 107 IU/mL for sample 4. The relative potencies of
























4.5 5.0 5.5 6.0 6
Fig. 2. Potencies of sample 2 relative to sample 1 (A), sample 3 relative to sample 1 (B), and
expressed as candidate log10 IU/mL in both cases. Each box represents the relative potency
from the qualitative assays are shaded in grey.quantitative and qualitative assay, are shown in histogram form in
Fig. 3. The overall mean potency estimates in candidate log10 IU/mL,
for samples 1e3 relative to sample 4, for quantitative and qualita-
tive assays, are shown in Table 5. These results show that when the
puriﬁed DNA sample 4 is used as a standard, there is no improve-
ment in agreement between laboratories, as compared with Fig. 1.
The SD between laboratories has increased from approximately 0.5
log10 to 0.64 log10, while the %GCVs have increased to over 300%.3.5. Intra-laboratory variation
Supplementary Table 3 shows the intra-laboratory SDs and %
GCVs for each laboratory, calculated by pooling the HCMV viral load
estimates for samples 1e3, but separately for sample 4. For all
samples, the inter-laboratory variation was greater than the intra-
laboratory variation (p < 0.0001). For samples 1e3, there were
differences between the repeatability of laboratory estimates
across assays (mean SD of 0.11 log10, mean %GCV of 30%). For4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5
4 - Relative to Sample 1
Candidate IU/ml (log10)
.5 7.0 7.5 8.0 8.5 9.0 9.5
sample 4 relative to sample 1(C), for each quantitative and qualitative assay. Units are
for each laboratory assay and is labelled with the laboratory code number. The results
Table 4
Overall mean estimates and inter-laboratory variation for potency (log10 IU/mL)
relative to sample 1, taking sample 1 as 5  106 (6.7 log10) IU/mL.
Sample Assay No. of datasets Mean Range SD %GCV
2 qualitative 5 6.62 6.02e7.16 0.42 163
quantitative 53 6.70 6.31e6.90 0.12 31
combined 58 6.69 6.02e7.16 0.16 44
3 qualitative 5 6.56 5.73e6.84 0.47 192
quantitative 52 6.69 6.42e7.46 0.19 56
combined 57 6.68 5.73e7.46 0.23 68
4 qualitative 5 7.52 6.83e8.23 0.58 280
quantitative 48 7.12 6.11e8.99 0.64 341
combined 53 7.16 6.11e8.99 0.64 340
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Fig. 3. Estimated concentrations (expressed in IU) of sample 1 relative to sample 4 (A), sample 2 relative to sample 4 (B), and sample 3 relative to sample 4 (C), using a hypothetical
unitage of 107 IU/mL for sample 4. Each box represents the relative potency for each laboratory assay and is labelled with the laboratory code number. The results from the
qualitative assays are shaded in grey.
Table 5
Overall mean estimates and inter-laboratory variation for potency (log10 IU/mL)
relative to sample 4, taking sample 4 as 107 (7.0 log10) IU/mL.
Sample Assay No. of datasets Mean Range SD %GCV
1 qualitative 5 6.18 5.47e6.87 0.58 280
quantitative 48 6.58 4.71e7.59 0.64 341
combined 53 6.54 4.71e7.59 0.64 340
2 qualitative 5 6.10 5.61e6.70 0.51 221
quantitative 48 6.59 4.70e7.73 0.64 333
combined 53 6.54 4.70e7.73 0.64 334
3 qualitative 5 6.04 5.61e6.94 0.54 246
quantitative 47 6.60 4.97e7.68 0.63 325
combined 52 6.54 4.97e7.68 0.64 334
J.F. Fryer et al. / Biologicals 44 (2016) 242e251248sample 4, the intra-laboratory variability was greater (mean SD of
0.21 log10, mean %GCV of 63%).
4. Discussion
The clinical management of an increasing number of infectious
diseases is dependent on molecular detection and quantiﬁcationmethods in order to guide treatment. Viral load measurements
need to be accurate and comparable across the range of assays in
use in order to establish optimal treatment strategies. In the past,
NIBSC has collaborated with the WHO ECBS in supporting the
introduction of NAT assays into the blood safety ﬁeld, through the
development of International Standards and other reference ma-
terials for blood-borne viruses. These materials have helped to
J.F. Fryer et al. / Biologicals 44 (2016) 242e251 249standardize assays and improve the quality of data produced. Here
we describe work to apply these same principles to support the
need to standardize NAT assays used in themolecular diagnosis of a
clinical virus, namely HCMV. The aim was to make a large batch of
aliquots of a stable and homogeneous preparation suitable for a
range of NAT-based assays.
A number of candidate materials were prepared and evaluated
for their suitability as a HCMV International Standard. These
included whole virus (liquid) preparations of Merlin and AD169
strains, puriﬁed Merlin DNA cloned into a BAC and a lyophilized
whole virus preparation of the Merlin strain. Merlin and AD169
were selected for the study as they represent the prototype clinical
and laboratory HCMV strains respectively. Merlin is a low-passage
strain with a near-complete genome that has been fully
sequenced (GenBank Accession number AY446894). Meanwhile,
AD169 contains several deletions (up to 15 kb in size), compared
with wild-type isolates. As the prototype laboratory strain, AD169
DNA is frequently used as a calibrator in HCMV NAT. Merlin and
AD169 also represent different genotypes of HCMV, classiﬁed as
genotype 1 and 2 viruses, respectively, based on the glycoprotein B
gene.
The formulation of whole virus preparations enables the can-
didates to be extracted alongside assay controls and clinical sam-
ples, thereby standardizing the entire HCMV assay, including both
extraction and DNA ampliﬁcation steps. Compared with the blood-
borne viruses, where virus is principally detected in one sample
matrix (i.e. plasma), the design of a reference material for a clinical
virus such as HCMV is particularly challenging, because of the
number of substrates inwhich the virus is detected. Given the wide
range of samples that are routinely tested for HCMV, and the
different extractionmethods designed to process each sample type,
the whole virus candidates were formulated in a universal Tris-HSA
buffer, to allow for further dilution in the appropriate sample ma-
trix used in each laboratory assay. The intention here was to pro-
vide a single reference material for HCMV that could be processed
using all extraction protocols available for HCMV-positive samples.
A preparation of Merlin DNA cloned into a BAC was included in the
study, in order to investigate the effect of the extraction step on the
variability in HCMV quantiﬁcation, and to determine whether a
puriﬁed DNA sample is suitable for standardizing HCMV viral load
measurements.
A lyophilized Merlin whole virus candidate was prepared, to
enable shipping at ambient temperatures, and for long-term sta-
bility. Data from accelerated thermal degradation studies did not
show any evidence for degradation after storage at elevated tem-
peratures for 5 years. As there is no observed drop in potency, it was
neither possible to ﬁt the usual Arrhenius model for accelerated
degradation studies, nor to obtain any predictions for the expected
loss per year with long-term storage at 20 C. However, using the
‘rule of thumb’ that the decay rate will approximately double with
every 10 K increase in temperature, and noting that there is no
detectable drop in potency after 60 months at 20 C, then there
should be no detectable difference after 480 months (40 years)
at20 C. A similar argument applied to the 37 C datawould imply
no detectable loss after more than 100 years at 20 C. Overall, the
available data indicates adequate stability for the lifetime of the
standard which is expected to be 10e15 years. All of the candidate
preparations were determined to be homogeneous in terms of the
HCMV DNA content by PCR.
In the collaborative study, all assays detected both Merlin and
AD169 strains, demonstrating the suitability of these HCMV strains
for use as candidate reference materials. The overall mean esti-
mates for the Merlin and AD169 whole virus candidates (samples
1e3) were ~5  106 (6.7 log10) ‘copies/mL’. This is slightly lower
than the original target concentration of 1  107 ‘copies/mL’ and islikely to be due to the small subset of laboratories selected for
preliminary testing of the virus stocks, and the large inter-
laboratory variation observed in assay results. The overall range
in laboratory mean estimates for the whole virus study samples
1e3 was 2 log10 ‘copies/mL’. This variability reﬂects the range and
differences in diagnostic testing procedures between laboratories
and is similar to levels previously reported for HCMV NAT-based
assays [5,6]. The overall range in laboratory mean estimates for the
puriﬁed DNA sample 4 was higher. This was unexpected, since the
puriﬁed DNA sample 4 was not extracted. However, the spread was
principally due to outlying results from ﬁve assays (there was no
observed relationship between these ﬁve assays). Inter-laboratory
variability was signiﬁcantly greater than intra-laboratory vari-
ability. This was also reported by Pang et al., [5].
The agreement between laboratories for virus samples 2 and 3
wasmarkedly improvedwhen the potencies of these study samples
were expressed relative to the lyophilized Merlin candidate (sam-
ple 1). These results demonstrate the suitability of the virus-based
candidates to reduce the inter-laboratory variability of assays
testing similar whole virus samples, and conﬁrms the ability of the
Merlin candidate to calibrate secondary references comprising the
AD169 strain. When the puriﬁed Merlin BAC preparation, sample 4,
was used as the reference, it did not improve the agreement in
HCMV quantiﬁcation between laboratories. These results highlight
the extent to which the extraction step contributes to inter-
laboratory variability. They also imply that a reference standard
based on DNAwould not be suitable for the standardization of NAT
assays testing whole virus samples.
From the results of this collaborative study, the lyophilized
Merlin whole virus preparation was determined to be the optimal
candidate for a higher order reference for HCMV quantiﬁcation by
NAT. This candidate was established at the WHO ECBS meeting in
October 2010 as the 1st WHO International Standard for HCMV for
NAT-based assays, with an assigned potency of 5  106 Interna-
tional Units, when reconstituted in 1 mL of nuclease-free water
(NIBSC product code 09/162) [17]. The assignment of a unitage for a
1stWHO International Standard is arbitrary. However, in the case of
this study, a value of 5  106 IU was chosen as this represents the
consensus estimate for the candidate standard across all laboratory
assays. The assigned unitage does not carry an uncertainty associ-
ated with it's calibration. The uncertainty may therefore be
considered to be the variance of the vial content and was deter-
mined to be ±0.23%. As this study shows, the use of the term copy
number for virus quantiﬁcation by NAT can be misleading. Copy
number estimates are not necessarily equivalent to genuine
genome equivalent numbers, but are instead dependent upon
variables in the extraction and ampliﬁcation steps, and on the
quantiﬁcation controls used. As for the International Standards
established for the blood-borne viruses, there is no overall con-
version factor between copies and IUs for HCMV. Any conversion is
entirely restricted to an individual assay, and the calibration of this
assay to the International Standard. The HCMV International
Standard is intended to be used for the calibration of whole virus-
based secondary reference materials used in HCMV NAT assays.
This can be performed by assaying serial dilutions of both prepa-
rations in parallel, and determining the equivalent concentration of
the secondary reference in IU. Once reconstituted, the HCMV In-
ternational Standard should be diluted in the matrix appropriate to
the material being calibrated, and extracted and ampliﬁed in par-
allel with the secondary reference. For example, if the secondary
reference comprises whole virus in a plasma matrix, then it should
be tested in parallel with dilutions of the WHO International
Standard prepared in a plasma matrix. The stability of the material
when reconstituted has not been speciﬁcally determined. There-
fore, it is recommended that the standard is for single use only.
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HCMV in solid-organ transplantation recommend that HCMV as-
says are recalibrated and demonstrate colinearity to the WHO In-
ternational Standard, and that results are reported as IU/mL [4].
This study highlights the improved inter-laboratory agreement and
comparability of viral load datawhen assays are calibrated against a
common reference. It is hoped that in due course, harmonization of
HCMV measurements will allow for clinically relevant thresholds
for HCMV to be deﬁned in IU [3,4,18]. This would negate the need
for individual laboratories to establish their own cut-offs for HCMV
management, and would allow patients to be managed at multiple
care centres.
The ability of the lyophilized Merlin candidate to reduce inter-
laboratory variability in HCMV quantiﬁcation for the samples
investigated in this study, does not guarantee that, when widely
implemented, the HCMV International Standard will harmonize
HCMV assays in the same way. The accuracy of measurement of a
virus in a clinical sample relies on the ability of the reference or
control samples to behave like clinical samples, i.e. to demonstrate
commutability. According to ISO guidelines [19], commutability
needs to be demonstrated for all references used in the measure-
ment process, i.e. secondary and tertiary references and the higher
order reference against which they are calibrated. Commutability
can be affected by a range of factors includingmatrix andmolecular
variants of the analyte (in this case HCMV DNA). The commutability
of the lyophilized Merlin candidate for HCMV-positive clinical
samples was not speciﬁcally assessed in this study. However, the
choice of strain and formulation of this candidate was intended to
make it as similar as possible to the range of samples being
investigated for HCMV. It was not feasible to derive the candidate
bulk from HCMV-positive clinical material, as has been the case for
other WHO International Standards such as those for HAV, HBV and
HCV [20e22]. The purpose of formulating the candidate in a uni-
versal matrix was to try to control for matrix effects, as it allows for
subsequent dilution in the samplematrix appropriate to each assay.
In this study, the improved agreement of all assay results for
samples 2 and 3 when expressed relative to the candidate standard
was independent of the diluent matrix used. The lyophilized Merlin
candidate was derived from a crude cell-free preparation of HCMV
from cell culture, which comprises both whole virus and naked
HCMV DNA forms (as determined by DNase digestion experiments
e data not shown). Meanwhile, patient samples derived from pe-
ripheral blood are likely to comprise a range of HCMV forms
including whole and disrupted virions, and fragmented genomic
DNA, with different forms predominating in different blood com-
partments. Plasma and serum samples from renal transplant re-
cipients have been reported to contain highly fragmented HCMV
DNA [23]. Meanwhile, whole blood samples from the same patients
comprised a mixture of highly fragmented and large DNA forms,
some of which may have been derived from whole virus.
A full assessment of commutability would require the reference
material to be evaluated in all assays and alongside all sample types
for which it might be used. This is because commutability can only
be demonstrated for the assays and clinical samples for which the
reference has been assessed. This task is particularly challenging for
HCMV because of the number of assays in use (as highlighted in this
collaborative study), and also because of the range of sample types
that are tested. The difﬁculty in sourcing sufﬁcient volumes of
clinical material for such extensive studies would require pooling
or dilution of samples thereby potentially compromising matrix
effects. This difﬁculty means that commutability will most likely
need to be addressed in multiple studies.
Commutability of the HCMV International Standard with
HCMV-positive plasma samples has recently been evaluated [24].
In this study, forty HCMV-positive plasma samples (pooled seriallycollected samples from individual solid organ transplant patients),
were tested alongside dilutions of the HCMV International Stan-
dard by six laboratories performing six commercial and two LDT
assays. The data was analyzed using linear regression and corre-
spondence analysis approaches. The results showed that several of
the assays (or assay pairs) showed either reduced commutability or
noncommutability. While these assays comprise many different
reagents including assay-speciﬁc secondary standards, in this
study, it was not possible to determine what impact these variables
had on the observed altered commutability between different as-
says. Further studies are planned to investigate the commutability
of the HCMV International Standard with other HCMV-positive
sample matrices. In the meantime, the availability of the HCMV
International Standard provides a higher order reference, which
has been demonstrated in this present study, to be homogeneous
and stable, and to reduce the inter-laboratory variability for the
assays and samples assessed in this study. Whether this improve-
ment in the agreement for HCMVmeasurements will be seen for all
NAT assays will be reported in time. Any evidence for non-
commutability might restrict its use with speciﬁc assays or sam-
ple types and will be noted in the instructions for use that
accompany the standard.
In addition to ongoing commutability studies for the HCMV
International Standard, NIBSC is collaborating with the WHO ECBS
to support the standardization of NAT assays for other clinically-
important viruses. The 1st WHO International Standard for Eps-
teineBarr virus for NAT was established by the WHO ECBS in
October 2011 [25]. Similar projects are underway to establish In-
ternational Standards for BK virus, JC virus, adenovirus and human
herpesvirus 6. It is anticipated that the future availability of an
increasing number of higher order reference materials for
clinically-important viruses will improve the standardization of
viral load measurement and lead to better patient management.
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